CN109803664A - 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 - Google Patents

用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 Download PDF

Info

Publication number
CN109803664A
CN109803664A CN201780049693.5A CN201780049693A CN109803664A CN 109803664 A CN109803664 A CN 109803664A CN 201780049693 A CN201780049693 A CN 201780049693A CN 109803664 A CN109803664 A CN 109803664A
Authority
CN
China
Prior art keywords
group
carbon atoms
cell
substituted
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780049693.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·德扎尔基西安
N·诺伊瑟克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taga Biomedical Co
Original Assignee
Nicholas Neuss
Val-Chum SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicholas Neuss, Val-Chum SC filed Critical Nicholas Neuss
Priority to CN202510670682.5A priority Critical patent/CN121313845A/zh
Publication of CN109803664A publication Critical patent/CN109803664A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201780049693.5A 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 Pending CN109803664A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510670682.5A CN121313845A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350258P 2016-06-15 2016-06-15
US62/350,258 2016-06-15
PCT/CA2017/000151 WO2017214709A1 (en) 2016-06-15 2017-06-15 Reagents, compositions and methods for improving viability and function of cells, tissues and organs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510670682.5A Division CN121313845A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Publications (1)

Publication Number Publication Date
CN109803664A true CN109803664A (zh) 2019-05-24

Family

ID=60663810

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780049693.5A Pending CN109803664A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法
CN202510670682.5A Pending CN121313845A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510670682.5A Pending CN121313845A (zh) 2016-06-15 2017-06-15 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法

Country Status (9)

Country Link
US (2) US11446265B2 (https=)
EP (1) EP3471733B1 (https=)
JP (3) JP7009463B2 (https=)
CN (2) CN109803664A (https=)
AU (1) AU2017285486B2 (https=)
CA (1) CA3027682A1 (https=)
DK (1) DK3471733T3 (https=)
ES (1) ES2992544T3 (https=)
WO (1) WO2017214709A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111202737A (zh) * 2020-03-20 2020-05-29 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111704647A (zh) * 2020-06-15 2020-09-25 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
CN112375802A (zh) * 2020-11-06 2021-02-19 中国科学院城市环境研究所 评价白藜芦醇干预肺上皮细胞多环芳烃毒性效应的试剂或试剂盒及其应用和检测
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN118634317A (zh) * 2024-08-16 2024-09-13 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055817A1 (en) * 2017-09-14 2019-03-21 The Regents Of The University Of California EX VIVO CONSERVATION AND EXPANSION OF STEM CELLS
JP7404246B2 (ja) * 2018-02-14 2023-12-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー フォン・ヴィレブランド因子のレベルを調節する化合物、及び血液疾患の治療におけるそれらの使用
EP3833662B1 (en) 2018-08-20 2024-01-17 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
US20220023345A1 (en) * 2020-07-22 2022-01-27 Caladrius Biosciences, Inc. Compositions Comprising CD34+ Cells and Methods for Repairing a Lung Injury After Severe Virus Infection
WO2022212878A1 (en) * 2021-04-01 2022-10-06 The Regents Of The University Of California Human pluripotent stem cell-derived secretome as a biologic for prevention and treatment of neurodegenerative and apoptotic diseases

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1276209A (zh) * 2000-05-26 2000-12-13 北京大学医学部 雷公藤属植物提取物在预防和治疗神经系统疾病中的用途
WO2008021210A2 (en) * 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN101267779A (zh) * 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
CN101288671A (zh) * 2008-04-17 2008-10-22 首都医科大学 雷公藤单体化合物在提高腺相关病毒载体介导的基因表达效率及其对神经退行性疾病的辅助治疗中的用途
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
CN101756956A (zh) * 2009-03-25 2010-06-30 赵亚力 儿茶素在制备逆转录病毒整合酶抑制剂中的应用
CN102369014A (zh) * 2008-12-08 2012-03-07 西北大学 调节hsf-i的方法
CN103524592A (zh) * 2013-09-27 2014-01-22 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
WO2015148802A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
US20100204093A1 (en) 2006-07-27 2010-08-12 University Of Florida Research Foundation, Inc Use of heat shock activators for tissue regeneration
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1276209A (zh) * 2000-05-26 2000-12-13 北京大学医学部 雷公藤属植物提取物在预防和治疗神经系统疾病中的用途
CN101267779A (zh) * 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
WO2008021210A2 (en) * 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
US20110218143A1 (en) * 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
CN101288671A (zh) * 2008-04-17 2008-10-22 首都医科大学 雷公藤单体化合物在提高腺相关病毒载体介导的基因表达效率及其对神经退行性疾病的辅助治疗中的用途
CN102369014A (zh) * 2008-12-08 2012-03-07 西北大学 调节hsf-i的方法
CN101756956A (zh) * 2009-03-25 2010-06-30 赵亚力 儿茶素在制备逆转录病毒整合酶抑制剂中的应用
CN103524592A (zh) * 2013-09-27 2014-01-22 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
WO2015148802A1 (en) * 2014-03-26 2015-10-01 The Children's Medical Center Corporation Celastrol and derivatives for the treatment of obesity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDREW DAVENPORT1 ET AL: "Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells", 《INT J MOL MED.》 *
LADA KLAIC ET AL.: "Celastrol Analogs as Inducers of the Heat Shock Response. Design and Synthesis of Affinity Probes for the Identification of Protein Targets", 《ACS CHEM BIOL》 *
SUDHISH SHARMA & RACHANA MISHRA & BRANDON L ET AL: "Celastrol, an oral heat shock activator, ameliorates multiple", 《CELL STRESS AND CHAPERONES》 *
ZONGWEI WANG ET AL: "Broad targeting of angiogenesis for cancer prevention and therapy", 《SEMINARS IN CANCER BIOLOGY》 *
于新: "《天然食品添加剂》", 31 March 2014, 中国轻工业出版社 *
郭洪志等: "《脑源性多器官功能障碍综合征》", 30 April 2009, 山东科学技术出版社 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111202737A (zh) * 2020-03-20 2020-05-29 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111202737B (zh) * 2020-03-20 2022-08-05 中国药科大学 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
CN111704647A (zh) * 2020-06-15 2020-09-25 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
CN111704647B (zh) * 2020-06-15 2021-10-22 中国人民解放军海军军医大学 一类三萜类衍生物及其作为程序性细胞坏死抑制剂的用途
CN112375802A (zh) * 2020-11-06 2021-02-19 中国科学院城市环境研究所 评价白藜芦醇干预肺上皮细胞多环芳烃毒性效应的试剂或试剂盒及其应用和检测
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN118634317A (zh) * 2024-08-16 2024-09-13 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途
CN118634317B (zh) * 2024-08-16 2024-10-22 四川大学 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途

Also Published As

Publication number Publication date
US20230024103A1 (en) 2023-01-26
US20210169830A1 (en) 2021-06-10
US11446265B2 (en) 2022-09-20
JP2022062037A (ja) 2022-04-19
CN121313845A (zh) 2026-01-13
EP3471733A4 (en) 2020-02-05
WO2017214709A8 (en) 2018-12-13
AU2017285486A1 (en) 2019-02-07
EP3471733B1 (en) 2024-08-07
DK3471733T3 (da) 2024-10-14
ES2992544T3 (es) 2024-12-13
JP7009463B2 (ja) 2022-01-25
EP3471733A1 (en) 2019-04-24
JP2019523784A (ja) 2019-08-29
CA3027682A1 (en) 2017-12-21
AU2017285486B2 (en) 2023-04-27
US12419849B2 (en) 2025-09-23
JP2024019483A (ja) 2024-02-09
WO2017214709A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
CN109803664A (zh) 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法
Thom et al. Stem cell mobilization by hyperbaric oxygen
US11110126B2 (en) Method of expanding NK cell and composition for culturing
KR101730052B1 (ko) 심근경색의 수복 재생을 유도하는 다능성 간세포
JP2020502078A (ja) ミトコンドリアを含む医薬組成物
KR20140040696A (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
KR20190004307A (ko) 시냅스 형성제
US12467035B2 (en) Method of differentiating mesenchymal stem cells into cardiomyocytes
RU2739996C1 (ru) Способ коррекции хронической печёночной недостаточности
KR20180136195A (ko) 줄기세포를 멜라토닌 처리 하여 증식 촉진 또는 생존율을 증가시키는 방법
Yang et al. Serum from radiofrequency-injured livers induces differentiation of bone marrow stem cells into hepatocyte-like cells
US12599631B2 (en) Agent for treating or preventing vascular dementia
JP7442624B2 (ja) 肢虚血を治療するための活性化間葉系幹細胞
HK40008604A (zh) 用於改善细胞、组织和器官的活力和功能的试剂、组合物和方法
KR20190104897A (ko) 줄기세포의 티오레독신 발현을 증진시키는 방법
Song et al. Effect of hypoxic paracrine media on calcium-regulatory proteins in infarcted rat myocardium
KR20190037020A (ko) 줄기세포 활성화 유도제 스크리닝 방법
Chu et al. 410.8: Improving the safety of stem-cell-derived beta cell transplantation with an inducible safety switch
Firoj et al. Influence of Bone Marrow Stem Cell Transplantation on Cardiac Function in Remodeled Left Ventricle of Rats after AMI
KR101697437B1 (ko) 중간엽줄기세포의 심근유사세포 분화유도용 아피시딘 함유 조성물
KR101532944B1 (ko) 골수유래 세포의 이식성과를 향상시키는 세포감작방법
Yuwono et al. Oxidants and Antioxidants in Medical Science
Triolo et al. Transplantation and Regeneration in the Heart of the Mediterranean
Colon-Jimenez Factors limiting spontaneous repair and their relevance for the efficiency of stem cell therapy of infarcted hearts
Li et al. Chemiric Tolerogenic Regulatory CD8+ T Cells Induced By Trogocytosis, a Bridge To Immune Tolerance.: Abstract# LB-13

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20191205

Address after: Kaisan ohokkatsu

Applicant after: DER SARKISSIAN SHANT

Applicant after: Nicholas Neuss

Address before: Kaisan ohokkatsu

Applicant before: DER SARKISSIAN SHANT

Applicant before: Nicholas Neuss

Applicant before: VAL-CHUM SOCIETE EN COMMANDITE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008604

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250102

Address after: Canada

Applicant after: Taga Biomedical Co.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: DER SARKISSIAN SHANT

Country or region before: Canada

Applicant before: Nicholas Neuss

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40008604

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190524